PharmaFocus Today – Page 11 – media

This tech giant is spending a whopping 2 billion yuan to accelerate its “AI transformation.”

Recently, Sanofi officially announced that it will invest US$294 million (approximately RMB 2 billion) to expand its global AI Center of Excellence in Toronto. According to the official announcement, this expansion also received a matching grant of up to $5 million from the Ontario Investment Fund . The project is expected to create 50 new high-end professional positions in artificial intelligence, machine learning, and data science by 2028. Prior to this, the center already had more than 150 positions, covering multiple professional fields such as cloud computing, data engineering, software development, bioinformatics, and pharmaceutical data science . The newly recruited talent will be responsible for designing and implementing various AI tools within Sanofi, applying them comprehensively to all aspects of the business, including drug development, manufacturing, and commercial operations. Sanofi’s Chief Digital Officer, Emmanuel Frenehard, publicly stated that artificial intelligence has been deeply integrated into the entire process of research, ...
- Source: drugdu
- 88
- May 8, 2026
Yuandong Bio takes the lead! China’s first acetaminophen-oxycodone extended-release tablets approved

Recently, according to the NMPA website, Chengdu Yuandong Biopharmaceutical Co., Ltd.’s improved new drug, acetaminophen oxycodone extended-release tablets , submitted under the Class 2.2 chemical drug category , has been approved for marketing, making it the first company in China to obtain approval for this dosage form. Acetaminophen/oxycodone extended-release tablets are a potent, centrally acting analgesic composed of the opioid analgesic oxycodone and the nonsteroidal anti-inflammatory drug acetaminophen. The two work synergistically to ensure analgesic efficacy while optimizing medication safety. Compared to domestically marketed acetaminophen/oxycodone immediate-release tablets, its core innovation lies in its dual-layer tablet design —one immediate-release layer and one extended-release layer —achieving long-lasting and stable analgesia, effectively reducing dosing frequency, and significantly improving patient adherence .According to the “China Pain Medicine Development Report,” there are over 300 million chronic pain patients in China, and this number continues to grow by 10-20 million annually, indicating a huge and rigid ...
- Source: drugdu
- 77
- May 8, 2026
Amgen’s innovative drug Evodia® (romoxozimab injection) has been approved in China, helping osteoporosis patients improve their bone health.

Amgen China announced that Evonik® (romoxozimab injection) has been approved by the National Medical Products Administration of China for the treatment of osteoporosis in postmenopausal women at high risk of fracture. As the world’s first and only dual-action biologic that simultaneously promotes bone formation and inhibits bone resorption, the approval of Evonik® provides a new treatment option for osteoporosis patients in China, especially those at very high fracture risk. Studies show that the risk of refracture is highest within 1-2 years after a fracture, and women with a history of fracture have an 86% increased risk of refracture. One in five postmenopausal women with vertebral fractures will experience a new fracture within one year, and 45% of women with hip fractures have reported fragility fractures . The approval of Evonik® is based on the results of several pivotal clinical studies, including the pivotal Phase III clinical trials FRAME and ARCH. ...
- Source: drugdu
- 89
- May 8, 2026
Crizotinol Ointment Approved for Market Launch; Jiudian Topical Products Expands to New Indications

Recently, Jiudian Pharmaceutical’s Crizotinol Ointment officially received registration approval from the National Medical Products Administration, which is considered equivalent to passing the generic drug consistency evaluation. This product is a Class B drug covered by the National Medical Insurance Program and is suitable for the topical treatment of mild to moderate atopic dermatitis in children aged 3 months and older and adults. This approval marks a new breakthrough for Jiudian Pharmaceutical in the field of topical medications, further expanding the therapeutic indications of its topical product portfolio from the anti-inflammatory and analgesic field to the field of skin immune inflammation regulation. Atopic dermatitis is a chronic, relapsing, inflammatory skin disease, and its prevalence among children in my country is showing an increasing trend year by year. For a long time, topical treatment for mild to moderate atopic dermatitis has mainly relied on corticosteroids and calcineurin inhibitors. However, long-term use of ...
- Source: drugdu
- 83
- May 8, 2026
Shanghai Pharmaceuticals’ Rivaroxaban Tablets Receive Thai Drug Registration Certificate

Recently, rivaroxaban tablets produced by Changzhou Pharmaceutical Factory Co., Ltd., a subsidiary of Shanghai Pharmaceuticals, received a drug registration certificate issued by the Thai Food and Drug Administration, and the drug has been approved for marketing. Rivaroxaban tablets are primarily used to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; to treat and prevent deep vein thrombosis (DVT); to treat pulmonary embolism (PE); and to prevent venous thromboembolism (VTE) in patients with acute illness. Rivaroxaban tablets were originally developed jointly by Bayer and Janssen and were launched in the United States in 2011. In May 2025, Changzhou Pharmaceutical Factory’s rivaroxaban tablets obtained approval from the U.S. Food and Drug Administration. In October 2025, it obtained a drug registration certificate in Malaysia, and in February 2026, it obtained a drug registration certificate in Singapore. According to IQVIA database, the total sales of rivaroxaban tablets in ...
- Source: drugdu
- 71
- May 8, 2026
The world’s first biased GLP-1RA officially enters commercialization.

Today, the world’s first approved cAMP-biased GLP-1 receptor agonist, enoglutide injection (Xianweiying® ) , was simultaneously issued as the first batch of prescriptions nationwide at Peking University People’s Hospital and Zhongshan Hospital affiliated with Fudan University, marking the official entry of this innovative weight management therapy into the clinical application stage in China. Currently, there are two routes for the innovative development of GLP-1 receptor agonists. The traditional route uses GLP-1 as the core target, combined with other targets such as GIP and GCG. The biased signaling mechanism of enoglutin originates from the Nobel Prize-winning research on the structure and function of G protein-coupled receptors (GPCRs). The clinical use of enoglutin reflects a shift in weight management clinical practice from simply focusing on the rate of weight loss to a comprehensive consideration of tolerability, sustainability, and the overall patient experience. Addressing the Challenges of Long-Term Weight Management In recent years, ...
- Source: drugdu
- 116
- April 28, 2026
Breaking News! BeiGene Introduces a PD-1/VEGF Triple Antibody

On April 27, Huahui Anjian announced that it had entered into a global exclusive option, licensing and collaboration agreement with BeiGene for the novel tumor immunotherapy trispecific antibody HH160 , granting BeiGene an exclusive option involving the development, production and commercialization of the product. Under the agreement, BeiGene will pay Huahui Anjian an upfront payment of US$20 million. Huahui Anjian is entitled to an additional US$100 million exercise payment if BeiGene exercises its option. Upon achieving development and regulatory milestones, Huahui Anjian is entitled to payments of up to US$374 million. Upon achieving sales milestones, Huahui Anjian is entitled to payments of up to US$1.53 billion, and is also entitled to tiered licensing fees. In addition, both parties will actively negotiate and discuss BeiGene’s potential participation in Huahui Anjian’s financing, and the specific transaction terms and details will be determined through further negotiation. HH160 is a novel trispecific antibody developed ...
- Source: drugdu
- 117
- April 28, 2026
AstraZeneca’s dual immunotherapy has been approved for marketing in China for a new indication

AstraZeneca recently announced that the China National Medical Products Administration (NMPA) has officially approved durvalumab (trade name: Imfinzi® ) in combination with tramapimab (trade name: Imfinzi® ) for first-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC). In addition, durvalumab has also been approved as monotherapy for first-line treatment of adult patients with advanced or unresectable HCC. According to the “Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2026 Edition),” the number of new cases of primary liver cancer in China in 2022 was 367,700, accounting for 42.5% of global cases; the number of deaths from primary liver cancer in 2022 was 316,500, ranking second in both the number of deaths and the case fatality rate; the 5-year relative survival rate of liver cancer in the Chinese population was 14.4%, and the proportion of patients diagnosed at intermediate or advanced stages reached more than 50%. ...
- Source: drugdu
- 127
- April 28, 2026
A market worth hundreds of billions! Where is the next trump card in the cosmetic injection industry?

Driven by compliance reforms and stricter regulations, the medical aesthetics device industry is poised for a landmark transformation, with the overall market experiencing a dual surge driven by both consumer upgrades and technological advancements. The market size for injectable medical aesthetics products is projected to grow from 67 billion yuan in 2023 to 147 billion yuan in 2027, maintaining a high compound annual growth rate. However, within this multi-billion yuan market, the four main materials exhibit distinct competitive landscapes. This report, compiled by Yaozhi Medical Device Data based on data from multiple sources, systematically describes the size, growth rate, and structural evolution of the medical aesthetic injection product market, the competitive landscape of the four major materials, demand changes, and behavioral analysis. It aims to provide industry participants with data insights and trend analysis to assist in strategic decision-making and resource optimization. 01 Product Overview Injectable cosmetic products primarily achieve ...
- Source: drugdu
- 112
- April 28, 2026
Thirteen Class 1 new drugs have been approved for clinical trials! Innovent, Hansoh, Gan & Lee, and Health-One, among others, have entered the fray

In the past week, China has seen a number of new developments in clinical trial applications for innovative drugs . Data shows that from April 20th to April 26th, 2026, 13 Class 1 new drugs were approved for clinical trials, linked to 19 application numbers. These drugs cover chemical drugs, therapeutic biological products, and traditional Chinese medicine, involving multiple areas such as ADCs, bispecific antibodies, siRNA, small molecule inhibitors, anti-infective drugs, and innovative traditional Chinese medicines. This batch of products includes projects from companies such as Innovent Biologics, Hansoh Pharmaceutical, Gan & Lee Pharmaceuticals, Health-One, and Qilu Pharmaceutical, as well as new developments in innovative traditional Chinese medicine and anti-infective drugs. More noteworthy than the approval of individual products for clinical trials is the simultaneous advancement of different technological approaches to the clinical stage. Antibody drugs remained one of the most active areas last week. Last week, therapeutic biologics projects ...
- Source: drugdu
- 94
- April 28, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.